UP!

DSCO $3.5

DSCO target price
3.50
0
0
Discovery Laboratories Inc
Type
Public
Traded as NASDAQ:DSCO
Industry Healthcare – biotechnology
Founded 1992
Headquarters Warrington, Pennsylvania, United States
Key people

John G. Cooper
(Chief Executive Officer, President, Chief Financial Officer, and Director)
Thomas F. Miller Ph.D.
(Chief Operating Officer)

Mr. John A. Tattory
(Chief Accounting Officer) (Dec 31, 2012)
Services Respiratory critical care
Revenue $ 510.00K (Sep 30, 2013)
Number of employees
119 (Sep 30, 2013)
Website www.discoverylabs.com

John G. Cooper
(Chief Executive Officer, President, Chief Financial Officer, and Director)
Thomas F. Miller Ph.D.
(Chief Operating Officer)

Discovery Laboratories, Inc (NASDAQ:DSCO) is an American company which was set up in 1992 and now is based in Warrington, Pennsylvania, developing drug products (pulmonary medicine) for patients with respiratory disease. The company joined an alliance with Laboratorios del Dr. Esteve, S.A.

The major products of the company are Surfaxin (based on its capillary aerosol-generating technology) and Aerosurf. Surfaxin is a synthetic, peptide-containing (KL4) surfactant, similar to pulmonary surfactant, which is naturally in the lung for normal respiratory function. The drug is delivered by its capillary aerosol-generating technology to the lung. Aerosurf is a drug-device combination to prevent respiratory distress syndrome (RDS) in premature infants. In addition, the company also provides Afectair devices (disposable aerosol-conducting airway connectors).

In November 2013, Discovery Laboratories began its phase II clinical program of aerosolized KL4 since U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application. The phase II consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome (RDS)

In October 2013, Discovery Laboratories received the agreement of updating Surfaxin (lucinactant) Intratracheal Suspension from the U.S. Food and Drug Administration (FDA) to prevent respiratory distress syndrome (RDS) in premature infants.

In September 2012, Discovery Laboratories started the four research projects to explore the KL4 surfactant technology for acute lung injury (ALI). These projects are funded through government-sponsored, biodefense-related initiatives under the Project Bioshield Act of 2004 and the Pandemic and All Hazards Preparedness Act of 2006.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2015-03-18 Reiterated Rating Piper Jaffray Overweight $3.00
2014-08-19 Initiated Coverage Stifel Nicolaus Buy $5.00
2014-03-19 Lower Price Target Roth Capital $6.00 to $5.50
2013-11-11 Initiated Coverage Piper Jaffray Overweight $6.00
2012-08-24 Initiated Stifel Nicolaus Buy $5
2015-03-18 Reiterated Rating Piper Jaffray Overweight $3.00
2014-08-19 Initiated Coverage Stifel Nicolaus Buy $5.00
2014-03-19 Lower Price Target Roth Capital $6.00 to $5.50
2013-11-11 Initiated Coverage Piper Jaffray Overweight $6.00
2012-08-24 Initiated Stifel Nicolaus Buy $5

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In DSCO 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
Lee's Pharmaceutical Holdings Ltd 3.35%  (2853271) DSCO /
Fraser Craig President and CEO 2.33%  (1983690) AEGR / DSCO /
Simonson Steven SVP, Chief Development Officer 1.11%  (941756) DSCO /
Tattory John A VP, Principal Acct Officer 1.04%  (884215) DSCO /
CAPETOLA ROBERT J President/CEO 0.52%  (446025) DSCO /
COOPER JOHN G Exec. VP, CFO 0.06%  (47511) DSCO / RMTI /
SEGAL ROBERT-MD Sr VP, Chief Medical Officer 0.05%  (39415) DSCO /
Katzer Charles F SVP, Manufacturing Operations 0.02%  (20000) DSCO /
Miller Thomas F SVP, Commercial..& Corp. Dev. 0.02%  (14110) DSCO /
Cole Kathy Senior VP, Human Resources 0.02%  (13989) DSCO /
Leone John R 0.01%  (11250) DSCO / PTX / VPHM /
Hoy Thomas VP, Manufacturing 0.01%  (10781) DSCO /
Amick W Thomas 0.01%  (10614) DNDN / DSCO /
Templeton Mary B Esq Senior VP, General Counsel 0.01%  (9270) DSCO /
LOPEZ DAVID L Executive VP & Legal Counsel 0.01%  (8033) DSCO /
ROSENTHALE MARVIN E 0.01%  (6211) DSCO /
PEACOCK BRUCE 0.01%  (6211) AGTC / DRNA / DSCO / OPHT / OPTT /
MAHADY JOSEPH M 0.01%  (6211) ALB / DSCO /